Chronic Pain: Data Snapshot

,
Cannabis Patient Care, March/April 2022, Volume 3, Issue 1
Pages: 8-11

Here, Tetragram shares an overview of some of the top four areas users reported on related to pain to see what type of products they are finding useful, how they are consuming it, and more.

Chronic pain can be a symptom for many patients with various illnesses. On their website, Johns Hopkins Medicine defines chronic pain as long standing pain that persists beyond the usual recovery period or occurs along with a chronic health condition. Otha Smith’s Tetragram mobile app allows users to anonymously track cannabis products as well as the conditions or symptoms they are using it for. In their most recent collection of data, users reported muscle pain, joint paint, nerve pain, muscle spasms, injury pain, headache, migraine, abdominal pain, chronic back pain, surgical pain, and more. Here, Tetragam allows us to share an overview of some of the top four areas patients reported on related to pain to see what type of products they are finding useful to help manage their pain, how they are consuming it, and more. This data relates to patients that reported muscle pain, joint pain, nerve pain, and injury pain. Some data highlights from this set include:

  • Inhalation is still the most popular consumption method among consumers with an average of 83.35% across all four symptoms reported here.
  • The average consumer is still not completely satisfied or experiencing symptom relief with an average of 35.58% ofusers responding with a score of 5 for the overall rating in these four symptom categories.

Muscle Pain

Patients who selected muscle pain as their primary symptom equaled 1729 sessions. Of those sessions, 32.79 reported using THC, 17.13 reported THCA, 8 reported CBD, 4.83 reported THCV, 2.9 reported CBDA, and 0.13 reported CBDV in their product.

Joint Pain

Patients who selected joint pain as their primary symptom equaled 1503 sessions. Of those sessions, 32.5 reported using THC, 16.67 reported THCA, 8.62 reported CBD, 3.99 reported THCV, 2.84 reported CBDA, and 0.06 reported CBDV in their product.

Nerve Pain

Patients who selected nerve pain as their primary symptom equaled 977 sessions. Of those sessions, 32.9 reported using THC, 16.21 reported THCA, 9.72 reported CBD, 5.02 reported THCV, 2.79 reported CBDA, and 0.03 reported CBDV in their product.

Injury Pain

Patients who selected injury pain as their primary symptom equaled 688 sessions. Of those sessions, 33.79 reported using THC, 14.98 reported THCA, 7.19 reported CBD, 3.06 reported THCV, 1.7 reported CBDA, and 0.15 reported CBDV in their product.